Mast Cell Activation Syndrome Diagnosis and Presentation

Core Diagnostic Principles

• The American Academy of Allergy, Asthma, and Immunology states that persistent symptoms should direct clinicians to a different underlying diagnosis, as MCAS requires recurrent episodic symptoms affecting 2 or more organ systems concurrently 1
• The American Academy of Allergy, Asthma, and Immunology recommends that chronic increases in mediator levels or continuous symptoms are inconsistent with MCAS and may instead reflect other conditions such as systemic mastocytosis, functional gastrointestinal disorders, or unrelated pathology 1

Diagnostic Requirements

• The 2025 AGA guidelines emphasize that MCAS testing should only be considered when patients present with episodic symptoms suggesting a generalized mast cell disorder involving 2 or more physiological systems, including cutaneous, GI, cardiac, respiratory, and neuropsychiatric systems 2, 3
• The American Academy of Allergy, Asthma, and Immunology states that all three criteria must be met for MCAS diagnosis: episodic symptoms affecting ≥2 organ systems concurrently, documented acute increases in mast cell mediators, and clinical response to mast cell-targeted therapies 1
• The 2025 AGA guidelines specify that documented acute increases in mast cell mediators should include a serum tryptase increase of 20% above baseline plus 2 ng/mL during flares, measured 1-4 hours after symptom onset 2, 3

Clinical Presentation

• True MCAS presents with acute, recurrent episodes involving at least 2 organ systems simultaneously, including cardiovascular, dermatologic, respiratory, and gastrointestinal systems 1
• The American Academy of Allergy, Asthma, and Immunology notes that cardiovascular symptoms may include hypotension, tachycardia, syncope or near-syncope 1
• The American Academy of Allergy, Asthma, and Immunology notes that dermatologic symptoms may include urticaria, pruritus, flushing, and angioedema, particularly of the eyelids, lips, and tongue 1
• The American Academy of Allergy, Asthma, and Immunology notes that respiratory symptoms may include wheezing, shortness of breath, and inspiratory stridor 1
• The American Academy of Allergy, Asthma, and Immunology notes that gastrointestinal symptoms may include crampy abdominal pain, diarrhea, nausea, and vomiting 4

Differential Diagnosis

• The 2025 AGA guidelines note that mild persistent GI symptoms between flares are more consistent with disorders of gut-brain interaction, such as functional dyspepsia or IBS 2
• The 2025 AGA guidelines note that mild persistent GI symptoms between flares may also be consistent with comorbid conditions like POTS, which can cause chronic nausea, abdominal pain, and early satiety independent of MCAS 4
• The 2025 AGA guidelines note that mild persistent GI symptoms between flares may also be consistent with gastroparesis or other motility disorders, particularly if there's associated hypermobility spectrum disorder 3

Diagnostic Criteria for Mast Cell Activation Syndrome (MCAS)

Essential Clinical Features and Laboratory Testing

• The American Academy of Allergy, Asthma, and Immunology recommends that symptoms must involve ≥2 organ systems simultaneously, including cardiovascular, dermatologic, respiratory, and gastrointestinal systems, to qualify for MCAS testing 5
• The Journal of Allergy and Clinical Immunology suggests that 24-hour urine collection for N-methylhistamine, Leukotriene E4, and 11β-prostaglandin F2α can be used when serum tryptase is difficult to obtain during episodes or remains negative 5
• The American Academy of Allergy, Asthma, and Immunology recommends performing KIT D816V mutation testing using highly sensitive allele-specific oligonucleotide quantitative PCR (ASO-qPCR) on peripheral blood to identify clonal (primary) MCAS 5
• The Journal of Allergy and Clinical Immunology suggests that buccal swab for TPSAB1 α-tryptase copy number variation (CNV) testing can be used to diagnose hereditary α-tryptasemia 5

Treatment Response and Classification

• The American Academy of Allergy, Asthma, and Immunology recommends documenting clinical improvement with mast cell-targeted therapies, including H1 antihistamines, H2 antihistamines, oral cromolyn sodium, leukotriene antagonists, and aspirin, to complete the diagnostic triad 5
• The Journal of Allergy and Clinical Immunology suggests that patients can be classified as primary MCAS, secondary MCAS, or idiopathic MCAS based on the presence of KIT-mutated clonal mast cells, underlying IgE-dependent allergy or other reactive condition, or neither triggering reactive state nor KIT-mutated mast cells identified 5

Evidence‑Based Diagnostic Framework for Mast Cell Activation Syndrome (MCAS)

Clinical Criteria (Recurrent Multisystem Episodes)

• Recurrent acute episodes that involve at least two organ systems are mandatory for MCAS diagnosis【6】【7】.
• Typical organ‑system manifestations include:
  
  • Cardiovascular – hypotension, tachycardia, syncope【6】【8】.
  • Dermatologic – urticaria, flushing, angio‑edema (especially of eyelids, lips, tongue)【6】【8】.
  • Respiratory – wheezing, dyspnea, inspiratory stridor【6】【8】.
  • Gastrointestinal – crampy abdominal pain, diarrhea, nausea, vomiting【6】【8】.
• Chronic or persistent symptoms (i.e., symptoms present between episodes) argue against MCAS and suggest alternative diagnoses such as chronic urticaria, functional gastrointestinal disorders, or asthma【6】【7】.

Laboratory Criteria (Acute Mediator Elevations)

• Baseline tryptase must be measured during an asymptomatic period to establish an individual reference value【9】.
• Acute tryptase should be drawn 1–4 hours after symptom onset during an episode【6】【7】【9】.
• Diagnostic threshold: a rise of ≥20 % above baseline and an absolute increase of ≥2 ng/mL【6】【7】【9】.
• This rise must be documented in at least two separate episodes【6】【7】.
• When tryptase is unavailable or negative, additional mediators can be assessed:
  
  • Urinary leukotriene E4 (peak 0–6 h after episode)【6】.
  • Urinary 11β‑prostaglandin F2α (peak 0–3 h)【6】.
  • (24‑hour urinary N‑methylhistamine is mentioned but lacks a citation and is therefore omitted.)

Therapeutic Response Criterion

• Demonstrated clinical improvement with mast‑cell‑directed therapy (e.g., H1/H2 antihistamines, mast‑cell stabilizers, leukotriene antagonists) is required as a diagnostic criterion【6】【7】.

Differential Diagnosis (Conditions with Elevated Baseline Tryptase)

• Chronic elevation of baseline tryptase without episodic symptoms does not satisfy MCAS criteria【6】【7】.

Further Diagnostic Work‑up (When Core Criteria Are Met)

• Bone‑marrow biopsy is reserved for patients with persistent baseline tryptase > 20 ng/mL or strong suspicion of systemic mastocytosis【9】.
• After confirmation, patients should be referred to allergy specialists or dedicated mast‑cell centers for ongoing management【9】.

Key Pitfalls to Avoid

• Over‑diagnosis occurs when MCAS is assigned to isolated organ involvement, nonspecific symptoms, or absent mediator elevation【6】【7】.
• Persistent inter‑episode symptoms are a red flag against MCAS【6】【7】.